Transforming the treatment of diabetic foot ulcers
Foot ulcers are common in patients with diabetes, and may lead to serious complications, including amputation, if left untreated.1
ALTRAZEAL has been demonstrated to promote healing in diabetic foot ulcers (DFUs) and protect these wounds from infection – a leading cause of amputation. ALTRAZEAL binds tightly to the wound on the microcellular level and provides high moisture vapor transpiration. Although the precise mechanism of action has not been determined, it is believed that this close contact and high moisture vapor transpiration rate (MVTR) at the interface between the dressing and wound bed creates a negative pressure that stimulates the formation of granulation tissue.
Because many patients with DFUs may have reduced mobility, ALTRAZEAL is an excellent treatment choice because it is comfortable and flexible – it's designed to move and flex with the skin.1 ALTRAZEAL often requires no secondary dressing, and its flexibility and comfort may promote better compliance among patients who may be treated at home.
- Medline Plus. Available at: http://www.nlm.nih.gov/medlineplus/diabeticfoot.html. Accessed October 5, 2008.